K2X Appoints Serial Technology Entrepreneur Amit Vohra, Ph.D., to Board of Directors
Serial founder and CEO brings decades of experience commercializing breakthrough technologies and scaling early-stage companies.
Los Altos, California — July 15, 2026 — K2X Technology & Life Science, Inc. (“K2X” or the “Company”) today announced the appointment of Amit Vohra, Ph.D., to its Board of Directors. Dr. Vohra succeeds Mike Baghramian, who stepped down from the Board for personal reasons.
Dr. Vohra is a serial founder and chief executive with a track record of bringing breakthrough technology to market. He is Founder, President and CEO of Promaxo, a developer of compact, office-based MRI and robotic systems, and Founder and CEO of neuro42, which develops portable MRI and robotics for neurological imaging and interventions. Together, these companies are expanding access to advanced imaging technologies that have traditionally been limited to large hospital settings. He is also co-founder and director of 8chili Inc. and a director of Navaux, Inc.
Dr. Vohra has developed a repeatable approach to building disruptive technology companies—from identifying breakthrough innovations and assembling exceptional teams to navigating complex regulatory pathways and commercializing new products. These capabilities translate across industries and align closely with K2X’s investment strategy. He holds a Ph.D. in Mechanical Engineering from the University of Florida and an Executive MBA from the Fuqua School of Business at Duke University.
“Amit brings the operating discipline and scientific judgment that will serve K2X’s Board well as the Company grows,” said Paul M. Russo, Ph.D., Chief Executive Officer of K2X. “He has repeatedly built breakthrough technology companies from the ground up and understands how to transform scientific innovation into commercially successful businesses. His experience building and scaling disruptive companies is sector-agnostic, and it strengthens our Board as we broaden the technology and deep-tech side of the portfolio.”
“We also thank Mike Baghramian for his service and counsel during an important period for K2X, and we wish him the very best,” Dr. Russo added.
“K2X has built a distinctive and disciplined approach to early-stage investing,” said Dr. Vohra. “I am excited to join the Board and look forward to contributing to the Company’s next phase of growth.”
About K2X
K2X Technology & Life Science, Inc. is a Silicon Valley-based investment company with an evergreen investment model that is designed to provide investors with diversified exposure to a rigorously selected portfolio of early-stage technology and life sciences companies. Unlike traditional venture funds with fixed investment horizons, K2X operates on a continuous investment cycle—identifying, investing in, supporting, and realizing value from high-potential companies as they mature across multiple sectors and geographies. More information is available at www.k2x.capital.
Media & Investor Contact
Paul M. Russo, Ph.D.
Chief Executive Officer
K2X Technology & Life Science, Inc.
# # #
Important Notice
This communication is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offering of securities will be made only by means of a prospectus forming part of an effective registration statement filed with the U.S. Securities and Exchange Commission, or pursuant to an applicable exemption from registration. This communication contains forward-looking statements that involve risks and uncertainties; actual results may differ materially. Information herein is subject to change and should not be relied upon as definitive or complete. K2X undertakes no obligation to update such statements except as required by law.